These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 840562)

  • 1. Dietary essential fatty acids in cystic fibrosis.
    Rosenlund ML; Selekman JA; Kim HK; Kritchevsky D
    Pediatrics; 1977 Mar; 59(3):428-32. PubMed ID: 840562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fatty acids composition of plasma phospholipids and triglycerides in children with cystic fibrosis. The effect of dietary supplementation with an olive and soybean oils mixture.
    Caramia G; Cocchi M; Gagliardini R; Malavolta M; Mozzon M; Frega NG
    Pediatr Med Chir; 2003; 25(1):42-9. PubMed ID: 12920976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipids in cystic fibrosis.
    Rosenlund ML; Walsh EP; Scott DA; Kritchevsky D
    Curr Concepts Nutr; 1979; 8():219-27. PubMed ID: 393469
    [No Abstract]   [Full Text] [Related]  

  • 4. Negative effects of oral fatty acid supplementation on sweat chloride in cystic fibrosis.
    Lloyd-Still JD; Simon SH; Wessel HU; Gibson LE
    Pediatrics; 1979 Jul; 64(1):50-2. PubMed ID: 450561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of an organized lipid matrix on lipid absorption and clinical outcomes in patients with cystic fibrosis.
    Lepage G; Yesair DW; Ronco N; Champagne J; Bureau N; Chemtob S; Bérubé D; Roy CC
    J Pediatr; 2002 Aug; 141(2):178-85. PubMed ID: 12183711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A therapeutic trial of fatty acid supplementation in cystic fibrosis.
    Elliott RB
    Pediatrics; 1976 Apr; 57(4):474-9. PubMed ID: 1264542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence of essential fatty acid deficiency in cystic fibrosis despite nutritional therapy.
    Aldámiz-Echevarría L; Prieto JA; Andrade F; Elorz J; Sojo A; Lage S; Sanjurjo P; Vázquez C; Rodríguez-Soriano J
    Pediatr Res; 2009 Nov; 66(5):585-9. PubMed ID: 19851226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis.
    Rettammel AL; Marcus MS; Farrell PM; Sondel SA; Koscik RE; Mischler EH
    J Am Diet Assoc; 1995 Apr; 95(4):454-9. PubMed ID: 7699188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Supplemental calories improve essential fatty acid deficiency in cystic fibrosis patients.
    Parsons HG; O'Loughlin EV; Forbes D; Cooper D; Gall DG
    Pediatr Res; 1988 Sep; 24(3):353-6. PubMed ID: 3211621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral DHA supplementation in DeltaF508 homozygous cystic fibrosis patients.
    Van Biervliet S; Devos M; Delhaye T; Van Biervliet JP; Robberecht E; Christophe A
    Prostaglandins Leukot Essent Fatty Acids; 2008 Feb; 78(2):109-15. PubMed ID: 18276127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential fatty acid deficiency in relation to genotype in patients with cystic fibrosis.
    Strandvik B; Gronowitz E; Enlund F; Martinsson T; Wahlström J
    J Pediatr; 2001 Nov; 139(5):650-5. PubMed ID: 11713441
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies of the effects of cis, cis and trans, trans-octadecadienoic acids on lipid metabolism in essential fatty acid deficient rats (author's transl)].
    Sano M
    Hokkaido Igaku Zasshi; 1981 Jan; 56(1):75-87. PubMed ID: 7262821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fatty acids platelets and oxidative markers following intravenous n-3 fatty acids administration in cystic fibrosis: An open pilot observational study.
    Durieu I; Vericel E; Guichardant D; Roth H; Steghens JP; Drai J; Josserand RN; Fontaine E; Lagarde M; Bellon G
    J Cyst Fibros; 2007 Sep; 6(5):320-6. PubMed ID: 17257908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Essential fatty acid deficiency and nutritional supplementation in cystic fibrosis.
    Lloyd-Still JD
    J Pediatr; 2002 Aug; 141(2):157-9. PubMed ID: 12183705
    [No Abstract]   [Full Text] [Related]  

  • 15. Intravenous linoleic acid supplementation in children with cystic fibrosis.
    Chase HP; Cotton EK; Elliott RB
    Pediatrics; 1979 Aug; 64(2):207-13. PubMed ID: 382082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fatty acid alterations and n-3 fatty acid supplementation in cystic fibrosis.
    Al-Turkmani MR; Freedman SD; Laposata M
    Prostaglandins Leukot Essent Fatty Acids; 2007; 77(5-6):309-18. PubMed ID: 18036797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cystic fibrosis of the pancreas. Diagnosis by sodium electrode sweat tests.
    Friedlmander S; Gasber RE; Lieb L
    Calif Med; 1969 May; 110(5):367-70. PubMed ID: 5771594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis.
    Jumpsen JA; Brown NE; Thomson AB; Paul Man SF; Goh YK; Ma D; Clandinin MT
    J Cyst Fibros; 2006 May; 5(2):77-84. PubMed ID: 16507353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term use of medium chain triglycerides in cystic fibrosis (author's transl)].
    Widhalm K; Götz M
    Wien Klin Wochenschr; 1976 Sep; 88(17):557-61. PubMed ID: 997539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phrynoderma: is it an EFA deficiency disease?
    Ghafoorunissa ; Vidyasagar R; Krishnaswamy K
    Eur J Clin Nutr; 1988 Jan; 42(1):29-39. PubMed ID: 3371295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.